Company Profiles

driven by the PitchBook Platform

nLife Therapeutics

Description

Developer of pharmaceutical products designed to create novel genetic medicines based on cell-specific delivery of nucleic acids. The company's pharmaceutical products are developed using cell-specific oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders, enabling doctors to get un-druggable target proteins and have potential as a disease-modifying therapy for a broad array of genetic disorders that might otherwise have no viable treatment option.

2009

Founded

PRIVATE

Status

11-50

Employees

Grant

Latest Deal Type

$350k

Latest Deal Amount

$19.3M

Total Amount Raised

Description

Developer of pharmaceutical products designed to create novel genetic medicines based on cell-specific delivery of nucleic acids. The company's pharmaceutical products are developed using cell-specific oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders, enabling doctors to get un-druggable target proteins and have potential as a disease-modifying therapy for a broad array of genetic disorders that might otherwise have no viable treatment option.

Website:

www.n-life.es

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery
Drug Delivery

Primary Office

Parque Tecnológico de Ciencias de la Salud, Eficio Bic-Granada, Nave 5 Avda. de la Innovacion, 1 18100 ArmillaSpain +34 95 750 599
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore nLife Therapeutics's full profile, request a free trial.

    nLife Therapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    nLife Therapeutics Investors (6)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Caixa Capital RiscCorporate Venture CapitalMinority000 0000000 0000
    Cross Road BiotechVenture CapitalMinority000 0000000 0000
    Healthequity (Spain)Venture CapitalMinority000 0000000 0000
    Inversión y Gestión de Capital Riesgo de AndalucíaVenture CapitalMinority000 0000000 0000
    Michael J. Fox FoundationOther000 0000000 0000
    Caixa Capital Risc Corporate Venture Capital
    Cross Road Biotech Venture Capital
    Healthequity (Spain) Venture Capital
    Inversión y Gestión de Capital Riesgo de Andalucía Venture Capital
    Michael J. Fox Foundation Other

    nLife Therapeutics Executive Team (6)

    NameTitleBoard
    Seat
    Contact
    Info
    Errol De Souza Ph.DChief Executive Officer & Executive Chairman
    Federico GregoGeneral Manager
    Raquel Revilla Sanchez Ph.DPrincipal, Neurodegenerative Diseases
    Theresa BranchekChief Scientific Officer
    Andres MontefeltroFounder & Senior Vice President, Research
    Errol De Souza Ph.D Chief Executive Officer & Executive Chairman
    Federico Grego General Manager
    Raquel Revilla Sanchez Ph.D Principal, Neurodegenerative Diseases
    Theresa Branchek Chief Scientific Officer
    Andres Montefeltro Founder & Senior Vice President, Research

    nLife Therapeutics Board Members (2)

    NameRepresentingRoleSinceContact
    Info
    José Antonio MesaCaixa Capital RiscInvestment Director000 0000
    Ronald Lorijn Ph.DnLife TherapeuticsBoard Member000 0000
    José Antonio Mesa Investment Director Caixa Capital Risc
    Ronald Lorijn Ph.D Board Member nLife Therapeutics
    Request full access to PitchBook